Associated Papers
Discriminating activating, deactivating and resistance variants in protein kinases.
Singh G et al.
Genome Medicine, 2025
Unveiling the Landscape of Uncommon EGFR Mutations in NSCLC-A Systematic Review.
Borgeaud M et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2024
EGFR Mutation Detection in Brazilian Patients With Non-Small-Cell Lung Cancer: Lessons From Real-World Data Scenario of Molecular Testing.
Montella T et al.
Jco Global Oncology, 2023
Structure-Guided Strategies of Targeted Therapies for Patients with EGFR-Mutant Non-Small Cell Lung Cancer.
Du Z et al.
Biomolecules, 2023
ERBB family fusions are recurrent and actionable oncogenic targets across cancer types.
Schubert L et al.
Frontiers in Oncology, 2023
Upfront Next Generation Sequencing in Non-Small Cell Lung Cancer.
Kuang S et al.
Current Oncology (toronto, Ont.), 2022
Driver gene alterations profiling of Chinese non-small cell lung cancer and the effects of co-occurring alterations on immunotherapy.
Sun S et al.
Cancer Medicine, 2021
Identification of the Unique Clinical and Genetic Features of Chinese Lung Cancer Patients With EGFR Germline Mutations in a Large-Scale Retrospective Study.
Lin X et al.
Frontiers in Oncology, 2021
Phase and context shape the function of composite oncogenic mutations.
Gorelick AN et al.
Nature, 2020
Heterogeneous Responses to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) in Patients with Uncommon EGFR Mutations: New Insights and Future Perspectives in this Complex Clinical Scenario.
Russo A et al.
International Journal of Molecular Sciences, 2019
Epidermal Growth Factor Receptor (EGFR) Kinase Inhibitors and Non-Small Cell Lung Cancer (NSCLC) - Advances in Molecular Diagnostic Techniques to Facilitate Targeted Therapy.
Ghafoor Q et al.
Pathology Oncology Research : Por, 2018
Epidermal growth factor receptor somatic mutation analysis in 354 Chinese patients with non-small cell lung cancer.
Quan X et al.
Oncology Letters, 2018
Epidermal growth factor receptor T790M mutation: A major culprit in the progression of epidermal growth factor receptor-driven non-small cell lung cancer and the role of repeat biopsy.
Aggarwal S et al.
Indian Journal of Cancer, 2017
Activation of the EGF Receptor by Ligand Binding and Oncogenic Mutations: The "Rotation Model".
Purba ER et al.
Cells, 2017
Clinical characteristics and response to tyrosine kinase inhibitors of patients with non-small cell lung cancer harboring uncommon epidermal growth factor receptor mutations.
Zhang Y et al.
Chinese Journal of Cancer Research = Chung-kuo Yen Cheng Yen Chiu, 2017
Examining Treatment Outcomes with Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Whose Tumors Harbor Uncommon EGFR Mutations.
Klughammer B et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2016
The impact of rare EGFR mutations on the treatment response of patients with non-small cell lung cancer.
Karachaliou N et al.
Expert Review of Respiratory Medicine, 2015
A systematic profile of clinical inhibitors responsive to EGFR somatic amino acid mutations in lung cancer: implication for the molecular mechanism of drug resistance and sensitivity.
Ai X et al.
Amino Acids, 2014
[Experience on epidermal growth factor receptor gene mutation analysis in non-small cell lung cancer].
Zhang J et al.
Zhonghua Bing Li Xue Za Zhi = Chinese Journal of Pathology, 2011
Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer.
Wu JY et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2011
Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma.
Bronte G et al.
Cancer Treatment Reviews, 2010
EGFR-mutated lung cancer: a paradigm of molecular oncology.
Zhang Z et al.
Oncotarget, 2010
Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop.
Pirker R et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2010
Epidermal growth factor receptor mutations in lung cancer.
Sharma SV et al.
Nature Reviews. Cancer, 2007
Epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer: impact of primary or secondary mutations.
Sakurada A et al.
Clinical Lung Cancer, 2006
Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer.
Chou TY et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2005
Epidermal growth factor receptor-activating mutation(E746_T751>VP) in pancreatic ductal adenocarcinoma responds to erlotinib, followed by epidermal growth factor receptor resistance-mediating mutation (A647T): A case report and literature review.
Patel GK et al.
Journal of Cancer Research and Therapeutics, 0
Targeting EGFR Exon 20 Insertion Mutations in Non-small-Cell Lung Cancer: Changes in Treatment Strategies are Coming.
Liu H et al.
Cancer Control : Journal of the Moffitt Cancer Center, 0